论文部分内容阅读
目的探讨和评估艾拉光动力疗法(ALA-PDT)治疗眼睑基底细胞癌的临床疗效。方法共有11例患者于2009年12月-2011年12月就诊于我科门诊并经过组织病理学检查结果确定为基底细胞癌,在我院首次接受ALA-PDT治疗。使用新鲜配制质量分数20%δ-氨基酮戊酸霜涂于病变及其周围0.5cm皮肤黏膜,塑料薄膜封包3-4h,然后用XO-635AB型光动力激光仪照射,观察患者治疗后的效果。结果 11例患者中有1例治疗1次后放弃治疗,其余经过3-5次治疗后经病理检查未见癌细胞,未见瘢痕形成。结论 ALA-PDT对于眼睑基底细胞癌患者来说,是一种具有良好的靶向性、安全可靠、治疗后无瘢痕、可重复使用、对正常皮肤无损害的治疗手段,患者有很好的耐受性,尤其适用于对其它疗法不能耐受、年龄太大和体弱的患者,是治疗眼睑基底细胞癌的一种新的替代疗法。
Objective To investigate and evaluate the clinical efficacy of ALA-PDT in the treatment of basal cell carcinoma of the eyelid. Methods A total of 11 patients were treated in our clinic from December 2009 to December 2011 and confirmed by histopathology as basal cell carcinoma. The first ALA-PDT treatment in our hospital. The use of freshly prepared mass fraction of 20% δ-aminolevulinic acid cream applied to the lesion and its surrounding 0.5cm skin mucosa, plastic wrap 3-4h, and then XO-635AB-type photodynamic laser irradiation to observe the effect of the patient after treatment . Results One of eleven patients gave up treatment after treatment for one time, and the remaining after 3-5 treatments did not see the cancer cells by pathological examination, no scar formation. CONCLUSIONS: ALA-PDT is a good and targeted therapy for patients with basal cell carcinoma of the eyelid, which is safe, reliable, non-scarred and reusable after treatment, and has no harm to normal skin. The patient has good resistance Acceptivity, especially for patients who are intolerant to other therapies, are over-age and infirm, is a new alternative to the treatment of basal cell carcinoma of the eyelid.